نتایج جستجو برای: interferon alfa

تعداد نتایج: 81290  

Journal: :Gut 2004
P J Thuluvath A Maheshwari J Mehdi K D Fairbanks L L-W Wu L G Gelrud M J Ryan F A Anania I F Lobis M Black

BACKGROUND AND AIM In this study, we compared the efficacy of triple therapy (interferon alfa, ribavirin, and amantadine) with standard therapy (interferon alfa and ribavirin) in treatment naïve patients with chronic hepatitis C virus (HCV). METHODS In this prospective, randomised, double blind, placebo controlled, multicentre study, 85 patients (amantadine group) received a three drug regime...

Journal: :Topics in HIV medicine : a publication of the International AIDS Society, USA 2010
David L Wyles

Numerous direct-acting drugs to treat hepatitis C virus (HCV) infection are in development, offering the potential for substantial improvement over current interferon alfa-based therapy and the possibility of effective interferon alfa-sparing regimens in achieving cure of HCV infection. Drugs furthest along in clinical development include HCV nonstructural protein 3 (NS3) protease inhibitors (e...

Journal: :Current oncology 2010
H Husein-Elahmed J L Callejas-Rubio R Ortega Del Olmo R Ríos-Fernandez N Ortego-Centeno

Melanoma is the most lethal form of skin malignancy because of its aggressive behaviour. In advanced disease, interferon alfa can be used as adjuvant therapy. However, this therapy is not free of side effects. We present a case of severe Raynaud syndrome and digital necrosis induced by interferon alfa in a patient with melanoma. Pathogenic mechanisms are discussed.

2003
P J Thuluvath L-W Wu L G Gelrud M J Ryan F A Anania

Background and aim: In this study, we compared the efficacy of triple therapy (interferon alfa, ribavirin, and amantadine) with standard therapy (interferon alfa and ribavirin) in treatment naı̈ve patients with chronic hepatitis C virus (HCV). Methods: In this prospective, randomised, double blind, placebo controlled, multicentre study, 85 patients (amantadine group) received a three drug regime...

Journal: :Lancet 2001
M P Manns J G McHutchison S C Gordon V K Rustgi M Shiffman R Reindollar Z D Goodman K Koury M Ling J K Albrecht

BACKGROUND A sustained virological response (SVR) rate of 41% has been achieved with interferon alfa-2b plus ribavirin therapy of chronic hepatitis C. In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ribavirin. METHODS 1530 patients with chronic hepatitis C were assigned interferon alfa-2b (3 MU subcutaneously three times per week) plus ...

Journal: :hepatitis monthly 0
kung-hung lin division of gastroenterology, department of internal medicine, kaohsiung veterans general hospital, kaohsiung, taiwan; physical examination center, kaohsiung veterans general hospital, kaohsiung, taiwan hsien-chung yu division of gastroenterology, department of internal medicine, kaohsiung veterans general hospital, kaohsiung, taiwan; division of gastroenterology, department of internal medicine, kaohsiung veterans general hospital, kaohsiung, taiwan. tel: +886-73422121, fax: +886-73468237 ping-i hsu division of gastroenterology, department of internal medicine, kaohsiung veterans general hospital, kaohsiung, taiwan wei-lun tsai division of gastroenterology, department of internal medicine, kaohsiung veterans general hospital, kaohsiung, taiwan wen-chi chen division of gastroenterology, department of internal medicine, kaohsiung veterans general hospital, kaohsiung, taiwan chun-ku lin division of gastroenterology, department of internal medicine, kaohsiung veterans general hospital, kaohsiung, taiwan

background rapid virological response (rvr) strongly predicts sustained virological response (svr) in patients with chronic hepatitis c (chc), and abbreviates antiviral therapy in some patients. objectives to identify factors predicting virological relapse (vr) in chc patients who attained rvr. patients and methods medical records of 133 chc patients with an rvr after completing 24 weeks of ant...

Journal: :Lancet 2008
Alexander M M Eggermont Stefan Suciu Mario Santinami Alessandro Testori Wim H J Kruit Jeremy Marsden Cornelis J A Punt François Salès Martin Gore Rona Mackie Zvonko Kusic Reinhard Dummer Axel Hauschild Elena Musat Alain Spatz Ulrich Keilholz

BACKGROUND Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability. METHODS 1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627) 6 mug/kg pe...

Journal: :The New England journal of medicine 2007
Gary Hudes Michael Carducci Piotr Tomczak Janice Dutcher Robert Figlin Anil Kapoor Elzbieta Staroslawska Jeffrey Sosman David McDermott István Bodrogi Zoran Kovacevic Vladimir Lesovoy Ingo G H Schmidt-Wolf Olga Barbarash Erhan Gokmen Timothy O'Toole Stephanie Lustgarten Laurence Moore Robert J Motzer

BACKGROUND Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease. METHODS In this multicenter, phase 3 trial, we randomly assigned 626 patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma to...

Journal: :The New England journal of medicine 2005
George K K Lau Teerha Piratvisuth Kang Xian Luo Patrick Marcellin Satawat Thongsawat Graham Cooksley Edward Gane Michael W Fried Wan Cheng Chow Seung Woon Paik Wen Yu Chang Thomas Berg Robert Flisiak Philip McCloud Nigel Pluck

BACKGROUND Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and lamivudine alone for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. METHODS A total of 814 patients with HBeAg-positive chron...

Journal: :Archives of internal medicine 1998
J Hayashi Y Kishihara K Ueno K Yamaji Y Kawakami N Furusyo Y Sawayama S Kashiwagi

BACKGROUND Interferon alfa is used widely for patients with chronic hepatitis C virus (HCV) infection. Little is known, however, of the relationship between patients' sex and the effectiveness of interferon alfa treatment in these patients. METHODS We treated 311 patients (199 men and 112 women) with human lymphoblastoid interferon (6 million units subcutaneously every day for 2 weeks and 3 t...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید